Taut

Taut is a biotechnology company focused on developing a new class of small molecule medicines that target the active, or "taut," conformations of proteins. By utilizing a proprietary platform for conformation-specific targeting, the company aims to stabilize specific protein states to modulate disease-relevant pathways that are otherwise difficult to address with traditional inhibitors. Taut's primary therapeutic focus is in oncology, specifically targeting the taurine transporter (TauT/SLC6A6) which is overexpressed in several cancers and plays a role in tumor survival and immune evasion. The company is also exploring applications in neurodegeneration and metabolic health, leveraging structural biology and cryo-EM insights to design high-affinity stabilizers. Taut is currently in the pre-clinical stage, advancing a pipeline of programs aimed at restoring cellular homeostasis and improving patient outcomes in intractable diseases.